Company

Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc., based in New York, is a clinical-stage company developing small-molecule cancer therapeutics.

About

Based in New York, US, and founded in 2014, Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company with operations in New York and San Diego. Anthony Sun is Chairman and CEO as of 2021. The company raised USD 85 million in Series C funding in 2019 and became a public company in April 2020, trading on Nasdaq as ZNTL. Its lead candidates are ZN-c5, for breast cancer, and ZN-c3, for solid tumors and ovarian cancer.

4Funding rounds

14Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in